Floatz logo

Uproleselan

Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

78 Active assets in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Uproleselan is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
51 / 100
View asset →
therapy-related myeloid neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →